EMJ GOLD

First Tracks Biotherapeutics’ experimental treatment reduced symptoms and helped prevent gut damage after gluten exposure.

The MHRA’s new strategy highlights how real-world evidence, AI-driven analysis, and clinician reporting could support better patient outcomes across healthcare. MHRA Chair, Anthony Harnden, shares his insights.

Bristol Myers’ RYZ101 improved progression-free survival in a Phase 3 trial for advanced neuroendocrine tumours.

Nvidia-backed Iambic seeks up to $159.4m in a US IPO as it develops experimental cancer treatments using AI.

The UK’s MHRA welcomes the ASA’s first bans on oral weight-loss medicine adverts and warns advertisers over rule breaches.

The ABPI group will allow teenagers to have a say in how the pharmaceutical industry recruits, communicates and builds trust with Gen Z.

Nobel Prize for Medicine goes to three scientists for their work on optogenetics, a process that has reshaped how scientists study the brain.

Foghorn is cutting around 40% of its workforce after disappointing trial results ended its cancer drug partnership with Lilly.